A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients

A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients

Gastrointestinal Stromal Tumor

Completed

1

Start Date 02/01/2013

Age of Trial (yrs) 11.8

Gleevec-resistant

KIT/PDGFRA inhibitor + PI3K inhibitor

Block KIT + Block KIT Signal Path

Specifically GIST and only GIST

CSTI571X2103, 2012-003273-25

Novartis

Novartis Pharmaceuticals 1-888-669-6682

Oral

A Dose-finding Phase Ib Multicenter Study of Imatinib in Combination With the Oral Phosphatidyl-inositol 3-kinase (PI3K) Inhibitor BYL719 in Patients With Gastrointestinal Stromal Tumor (GIST) Who Failed Prior Therapy With Imatinib and Sunitinib